Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LASIX vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease including nephrotic syndrome,Hypertension (off-label)
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (Cr Cl <20 m L/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Furosemide is metabolized primarily by glucuronidation via UGT1A1, with minimal hepatic metabolism; about 50% is excreted unchanged in urine.
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
91-99% bound, primarily to albumin.
Approximately 95% bound, primarily to albumin.
0.1-0.2 L/kg in healthy adults; increases in conditions with reduced plasma protein binding (e.g., nephrotic syndrome) or fluid overload (e.g., heart failure) up to 0.3-0.8 L/kg.
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Oral: 60-70% (range 50-80%); decreased by food; intravenous: 100%.
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
GFR 10-50 m L/min: dose every 12 hours; GFR <10 m L/min: avoid use or use with extreme caution.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or avoid.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
1-2 mg/kg/dose PO or IV every 6-12 hours; maximum 6 mg/kg/day.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Start at 20 mg/day PO or 20 mg IV, titrate slowly due to increased sensitivity and risk of electrolyte disturbances.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Furosemide is a potent diuretic. If given in excessive amounts, it can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Risk of hypovolemia, dehydration, and electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia, hypomagnesemia, hypocalcemia),Ototoxicity, especially with rapid injection or severe renal impairment,Sulfonamide cross-sensitivity
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Anuria,History of hypersensitivity to furosemide or sulfonamides
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
High sodium intake can counteract diuretic effects. Avoid excessive licorice consumption as it can worsen hypokalemia. Grapefruit juice may increase systemic exposure of furosemide; avoid concurrent use.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, decreased placental perfusion, electrolyte imbalances, and fetal dehydration; oligohydramnios reported. Use only if clearly needed.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Furosemide is excreted into breast milk in low amounts. M/P ratio approximately 1:1. No adverse effects reported in infants, but may suppress lactation. Use with caution, especially in neonates.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing furosemide exposure. Dose adjustments may be necessary to maintain efficacy; titration based on clinical response and monitoring recommended. No established dose modification guidelines; individualize therapy.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
For rapid diuresis in acute pulmonary edema, administer IV furosemide slowly over 1-2 minutes to avoid ototoxicity. Monitor serum potassium closely, especially in patients on digoxin or with hepatic cirrhosis. Higher doses (>80 mg) may require divided doses to prevent peak-related adverse effects.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Take furosemide exactly as prescribed, usually in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss of more than 2-3 pounds in a day.,Avoid prolonged sun exposure and use sunscreen as furosemide can increase sun sensitivity.,Do not stop taking this medication abruptly; tapering may be needed to avoid rebound fluid retention.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LASIX vs BUMETANIDE, answered by our medical review team.
LASIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LASIX and BUMETANIDE depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LASIX is: 20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LASIX and BUMETANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LASIX is classified as Category C. Furosemide crosses the placenta. First trimester: limited data, no clear teratogenic pattern; risk cannot be excluded. Second and third trimesters: may cause maternal hypovolemia, . BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.